HDAC9 and cancer: Finally, Wargo and colleagues [301] reported improved recognition of tumor cells by engineered peripheral blood lymphocytes in response to increased cancer-testis antigen NY-ESO-1 expression (typically expressed in the majority of epithelial tumors, including ovarian [302]), catalyzed by DNMT inhibitor (alone or combined with HDAC inhibitor).